3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Other hematologic neoplasm
1
Conditions
Neoplasms
10
Breast Neoplasms
9
Prostatic Neoplasms
7
Multiple Myeloma
6
Colorectal Neoplasms
5
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Leukemia, Myeloid, Acute
4
Head and Neck Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Recurrence
3
Neoplasms, Plasma Cell
3
Lung Neoplasms
3
Hematologic Neoplasms
3
Glioblastoma
3
Carcinoma, Ovarian Epithelial
3
Urinary Bladder Neoplasms
2
Neoplasms by Site
2
Mycoses
2
Medication Adherence
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Follicular
2
Leukemia
2
Carcinoma, Transitional Cell
2
COVID-19
2
Adenocarcinoma
2
Uveal Melanoma
1
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Neoplasms
1
Interventions
Rituximab
130
Cyclophosphamide
41
Bendamustine Hydrochloride
39
venetoclax
25
fludarabine
25
obinutuzumab
24
Lenalidomide
23
ibrutinib
22
Gemcitabine
22
Vincristine
20
Prednisone
20
tositumomab I-131
19
Doxorubicin
19
plerixafor
14
Dexamethasone
14
Granulocyte Colony-Stimulating Factor
12
pirtobrutinib
11
Brentuximab Vedotin
11
glofitamab
10
tocilizumab
9
pembrolizumab
9
ibritumomab tiuxetan
9
Etoposide
9
Azacitidine
9
polatuzumab vedotin
8
parsaclisib
8
copanlisib
8
acalabrutinib
8
Drug Therapy
8
ublituximab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma, Non-Hodgkin
×
Standard of Care
×
Clear all
NCT04844866
2026-04-29
DALY 2-EU
Miltenyi Biomedicine GmbH
Phase 2
Recruiting
213 enrolled
NCT03575351
2025-08-03
TRANSFORM
Celgene
Phase 3
Completed
184 enrolled
30 charts
1 FDA